Intervacc AB banner
I

Intervacc AB
STO:IVACC

Watchlist Manager
Intervacc AB
STO:IVACC
Watchlist
Price: 0.888 SEK 5.84% Market Closed
Market Cap: kr302.6m

Intervacc AB
Investor Relations

Intervacc AB engages in the development of novel veterinary vaccines. The company is headquartered in Hagersten, Stockholm and currently employs 15 full-time employees. The company went IPO on 2017-04-07. The company develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The firm operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. The company offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.

Show more
Loading
IVACC
OMX Stockholm 30
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Jonas Sohlman
Chief Executive Officer
No Bio Available
Mr. Jan Persson
Chief Financial Officer
No Bio Available
Mr. Patrik Hellberg
Chief Investment Officer
No Bio Available
Dr. Andrew Waller
Chief Scientific Officer
No Bio Available

Contacts

Address
STOCKHOLM
Hagersten
Vastertorpsvagen 135
Contacts
+46812010600
intervacc.se
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett